SAXENDA Drug Patent Profile

Which patents cover Saxenda, and when can generic versions of Saxenda launch?

Saxenda is a drug marketed by Novo and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has sixty-three patent family members in twenty-seven countries.

The generic ingredient in SAXENDA is liraglutide. There are seven drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the liraglutide profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Saxenda

A generic version of SAXENDA was approved as liraglutide by HIKMA on December 23^rd, 2024.

Summary for SAXENDA

International Patents:	63
US Patents:	2
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for SAXENDA

Paragraph IV (Patent) Challenges for SAXENDA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
SAXENDA	Injection	liraglutide	18 mg/3 mL prefilled syringe	206321	1	2021-08-16

US Patents and Regulatory Information for SAXENDA

SAXENDA is protected by two US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novo	SAXENDA	liraglutide	SOLUTION;SUBCUTANEOUS	206321-001	Dec 23, 2014	AP2	RX	Yes	Yes	8,114,833*PED				Y
Novo	SAXENDA	liraglutide	SOLUTION;SUBCUTANEOUS	206321-001	Dec 23, 2014	AP2	RX	Yes	Yes	9,968,659*PED				Y

International Patents for SAXENDA

See the table below for patents covering SAXENDA around the world.

Country	Patent Number	Title	Estimated Expiration
Japan	5185620
Poland	1819382
Spain	2243721
Japan	2008517233
Brazil	112018067344	liraglutida em condições cardiovasculares

Supplementary Protection Certificates for SAXENDA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0944648	C00944648/01	Switzerland		PRODUCT NAME: LIRAGLUTID; REGISTRATION NO/DATE: SWISSMEDIC 59329 11.12.2009
0944648	CA 2009 00041	Denmark
2209800	1490067-4	Sweden		PRODUCT NAME: COMBINATION OF INSULIN DEGLUDEC AND LIRAGLUTIDE; REG. NO/DATE: EU/1/14/974 20140918
0944648	09C0054	France		PRODUCT NAME: LIRAGLUTIDE; REGISTRATION NO/DATE IN FRANCE: EU/1/09/529/001 DU 20090630; REGISTRATION NO/DATE AT EEC: EU/1/09/529/001 DU 20090630
2209800	14C0085	France		PRODUCT NAME: LIRAGLUTIDE ET INSULINE DEGLUDEC; REGISTRATION NO/DATE: EU/1/14/947 20140918

Investment Scenario, Market Dynamics, and Financial Trajectory for SAXENDA (Liraglutide for Weight Management)

Last updated: February 3, 2026

Executive Summary

SAXENDA (liraglutide) is a glucagon-like peptide-1 receptor agonist (GLP-1 RA) approved primarily for weight management in individuals with obesity or overweight conditions. Originally developed for type 2 diabetes (marketed as Victoza), the drug's indication expansion for obesity since 2014 (FDA) and subsequent approvals worldwide has repositioned SAXENDA as a key player in the obesity pharmacotherapy segment. This analysis explores market potential, competitive landscape, financial outlook, and strategic insights for investors considering SAXENDA.

---

What Is the Current Market for SAXENDA?

Market Size and Growth Trends

Indicator	2022 Estimate	Projections 2027	CAGR (2022-2027)
Global Obesity Therapeutics Market	$10.2 billion	$15.8 billion	9.2%
Market for Obesity Drugs (SAXENDA focus)	$1.8 billion	$3.4 billion	14.2%
Patients Eligible for Pharmacotherapy	420 million	620 million	6.7%

Source: MarketsandMarkets, 2023; IQVIA, 2022.

Market Penetration and Adoption

• The global obesity market remains highly fragmented with key players like Novo Nordisk (Saxenda's parent company, Novo Nordisk A/S), Eli Lilly, and Pfizer.
• Saxenda, priced approximately $1,100/month, faces reimbursement and access hurdles but benefits from increasing awareness.
• Obesity management shifts toward pharmacotherapy amid rising healthcare costs and obesity-related comorbidities.

Key Market Drivers

Factor	Impact
Rising obesity prevalence	Expands eligible patient pool
FDA and global approvals of Saxenda	Extended market access
Lifestyle and behavioral therapy limitations	Increased reliance on pharmacological options
Patient demand for non-surgical options	Accelerates uptake

---

Market Dynamics and Competitive Landscape

Major Competitors and Alternatives

Competitor	Active Ingredient	Indication(s)	Market Share Est. (2022)	Notable Features
Novo Nordisk	Semaglutide (Wegovy)	Obesity, Diabetes	45%	Once-weekly dosing, superior efficacy
Eli Lilly	Tirzepatide	Obesity, Diabetes	20%	Dual GIP/GLP-1 receptor activity
Pfizer	Lorcaserin (withdrawn)	Weight loss (former)	-	Market exit due to safety concerns
Others	Orlistat, Phentermine, setliptin	Non-injectable alternatives	remainder	Variable efficacy, side effects

Source: EvaluatePharma, 2023; analysts' estimates.

Regulatory and Patent Landscape

• Saxenda’s patent protection extends until at least 2030, with recent patent filings intended to fortify exclusivity.
• Regulatory backing is robust; the drug holds approvals across US, EU, Japan, and other markets.

Market Entry Barriers

• Injectable administration limits some patient segments.
• Cost and insurance reimbursement constraints hamper rapid expansion.
• Competitive pipeline drugs rapidly emerging (e.g., semaglutide variants).

---

Financial Trajectory and Investment Outlook

Revenue Projections

Year	Estimated Revenue (USD millions)	Assumptions
2022	$1,200	Current market penetration
2023	$1,600	New approvals in emerging markets
2024	$2,300	Increased patient access, new indications
2025	$3,200	Broader insurer coverage, higher adoption
2026	$4,300	Market expansion, lifecycle management
2027	$5,800	Saturation in developed markets

Note: Based on a compounded annual growth rate (CAGR) of approximately 35%, factoring in market expansion and increased prescribing.

Profitability Considerations

• Gross margins are estimated at 70% due to subsidies and manufacturing efficiencies.
• Operating expenses, including R&D and marketing, projected to increase proportionally with sales.
• Break-even anticipated by 2024 if current growth rates persist.

Investment Risks and Mitigation

Risk Factor	Mitigation Strategies
Market penetration barriers	Pricing strategies, rebate negotiations
Competitive displacement	Lifecycle management, novel formulations, expanding indications
Regulatory hurdles	Ongoing compliance, pipeline diversification
Patent litigation	Active patent portfolio, legal vigilance

---

Comparison with Competitors

Criterion	SAXENDA	Wegovy (Semaglutide)	Tirzepatide
Dosing Frequency	Daily injection	Weekly	Weekly
Efficacy (Weight Loss)	~5-10% of body weight	Up to 15%	Up to 20%
Safety Profile	Similar to GLP-1	Similar	Similar
Price per Dose	~$35 (daily)	~$150 (weekly)	~$170 (weekly)
Global Approvals	Yes	Yes	Pending/Available in some markets

Implication: While Wegovy and Tirzepatide demonstrate higher efficacy, SAXENDA remains competitive in markets with existing infrastructure and patient acceptance of daily injections.

---

Regulatory Policy Impact

• Increasing global attention to obesity as a disease influences approvals and reimbursement.
• The US Inflation Reduction Act (2022) has introduced value-based frameworks for drug pricing, impacting profitability.
• Reimbursement policies are evolving, with more coverage for obesity drugs in Medicare/Medicaid.

---

Future Outlook and Strategic Opportunities

Opportunity	Details
Line extension via combination therapies	Combining liraglutide with other agents to enhance efficacy
Digital health integration	Apps and telemedicine to improve adherence
Geographic expansion	Entry into emerging markets with rising obesity rates
Indication expansion	Use in pediatric populations or related metabolic conditions

---

Key Takeaways

• Saxenda remains a significant player with established market presence, though facing competition from newer agents like semaglutide and tirzepatide.
• Growth potential is substantial, driven by rising global obesity prevalence and increasing acceptance of pharmacotherapy.
• Price sensitivity and reimbursement hurdles are primary challenges; strategic positioning and lifecycle management are critical.
• Differentiation through efficacy, patient convenience, and integrated health solutions can optimize long-term profitability.
• Regulatory and policy landscapes increasingly favor obesity-medication innovation, underscoring the importance of ongoing R&D.

---

FAQs

1. What is the main differentiator of SAXENDA compared to its competitors?
Saxenda’s primary advantage lies in its established safety profile, FDA approval for weight management since 2014, and a broad global footprint. However, newer agents demonstrate superior weight loss efficacy, which could influence patient and clinician preferences over time.

2. How does reimbursement influence SAXENDA's market growth?
Reimbursement policies significantly impact patient access. Countries with coverage for obesity drugs facilitate higher utilization, whereas lack of reimbursement or high co-payments hinder growth prospects.

3. What is the patent outlook for SAXENDA?
Patents extending to 2030 protect Saxenda’s formulation and delivery mechanisms, providing a window for market exclusivity. Patent challenges or generics could impact future revenues.

4. Are there upcoming pipeline developments for SAXENDA?
Exact pipeline plans are proprietary, but lifecycle management strategies include fixed-dose combinations, improved formulations, and expanded indications to sustain competitiveness.

5. What are the risks associated with investing in SAXENDA?
Risks include market competition from more efficacious drugs, reimbursement barriers, regulatory changes, and potential safety concerns. Diversification and ongoing innovation are vital mitigation strategies.

---

References

1. MarketsandMarkets. (2023). Global Obesity Therapeutics Market.
2. IQVIA. (2022). Global Prescribing Trends in Obesity Pharmacotherapy.
3. EvaluatePharma. (2023). Market Share and Revenue Estimates.
4. FDA. (2014). Approval of Saxenda for Weight Management.
5. Novo Nordisk. (2023). Investor Relations – Pipeline and Patent Portfolio.